Need professional-grade analysis? Visit stockanalysis.com
$531.33M
N/A
N/A
N/A
Zura Bio Limited Class A Ordinary Shares (ZURA) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $5.29, down 8.95% from the previous close.
Over the past year, ZURA has traded between a low of $1.00 and a high of $7.00. The stock has gained 267.4% over this period. It is currently 24.4% below its 52-week high.
Zura Bio Limited Class A Ordinary Shares has a market capitalization of $531.33M.
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Side-by-side comparison against top Healthcare peers.